Human immunodeficiency virus vaccine trials.
نویسندگان
چکیده
More than 2 million AIDS-related deaths occurred globally in 2008, and more than 33 million people are living with HIV/AIDS. Despite promising advances in prevention, an estimated 2.7 million new HIV infections occurred in that year, so that for every two patients placed on combination antiretroviral treatment, five people became infected. The pandemic poses a formidable challenge to the development, progress, and stability of global society 30 years after it was recognized. Experimental preventive HIV-1 vaccines have been administered to more than 44,000 human volunteers in more than 187 separate trials since 1987. Only five candidate vaccine strategies have been advanced to efficacy testing. The recombinant glycoprotein (rgp)120 subunit vaccines, AIDSVAX B/B and AIDSVAX B/E, and the Merck Adenovirus serotype (Ad)5 viral-vector expressing HIV-1 Gag, Pol, and Nef failed to show a reduction in infection rate or lowering of postinfection viral set point. Most recently, a phase III trial that tested a heterologous prime-boost vaccine combination of ALVAC-HIV vCP1521 and bivalent rgp120 (AIDSVAX B/E) showed 31% efficacy in protection from infection among community-risk Thai participants. A fifth efficacy trial testing a DNA/recombinant(r) Ad5 prime-boost combination is currently under way. We review the clinical trials of HIV vaccines that have provided insight into human immunogenicity or efficacy in preventing HIV-1 infection.
منابع مشابه
Tetanus and Diphtheria Seroprevalence in Patients Infected With Human Immunodeficiency Virus
Background and Objectives: HIV infected patients are at risk for vaccine-preventable infections such as tetanus and diphtheria (Td). In these patients, these antibodies tend to decline faster. Due to the limited data, this study assessed the seroprevalence of tetanus and diphtheria antibodies in HIV infected patients in Tehran, Iran. Materials and Methods: This case-control study was carried o...
متن کاملQuantification Analysis of Dot Blot Assays for Human Immunodeficiency Virus Type 1 and 2 Antibodies
Objective Dot Blot (DB) assay provides highly specific results, but usually not reliable for quantification of antibody production. The need for a more objective DB assay to provide a better definition of the immune status, against HIV antigens, promoted this study to be done to develop a quantitative DB assay. Material and Methods Dot blot (DB) strips for antibodies directed to human immuno...
متن کاملHIV Vaccine Efficacy Trial Feasibility in the United States Vermund Vaccine Efficacy Trials for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Are Feasible in the United States: A Commentary on the HIVNET Vaccine Preparedness Study
متن کامل
Cytomegalovirus Active Infection in Persons Infected with Human Immunodeficiency Virus
Background and Objective: Cytomegalovirus (CMV), one of the most common opportunistic pathogens in patients infected with human immunodeficiency virus (HIV), can cause the diseases such as encephalitis, pneumonia, and chorioretinitis. This study aimed at molecular studying of CMV infection in individuals infected with the human immunodeficiency virus. Material and Methods: In this study, 50 ven...
متن کاملThe Use of Chimpanzees in Biomedical and Behavioral Research
Prior to Simian Immunodeficiency Virus (SIV)-infected macaques becoming the ‘model of choice’ in the 1990s, chimpanzees were widely used in AIDS vaccine research and testing. Faced with the continued failure to develop an effective human vaccine, some scientists are calling for a return to their widespread use. To assess the past and potential future contribution of chimpanzees to AIDS vaccine ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cold Spring Harbor perspectives in medicine
دوره 2 12 شماره
صفحات -
تاریخ انتشار 2012